Tech Enhanced Investing

Parag Milk Foods is trading at Rate RS 271.40 on the BSE, gaining Rate RS 3.20 or 1.19% from its previous close of Rate RS 268.20.

The stock opened at Rate RS 268.95 and moved between an intraday high of Rate RS 279.50 and a low of Rate RS 265.70. A total of 752,904 shares have been traded on the BSE so far.

The company's BSE Group 'A' shares, with a face value of Rate RS 10, have recorded a 52-week high of Rate RS 377.20 on November 13, 2025, and a 52-week low of Rate RS 178.35 on March 30, 2026.

Over the past week, the stock has traded between Rate RS 246.90 and Rate RS 279.90. Parag Milk Foods currently has a market capitalisation of approximately Rate RS 3,392.09 crore.

Promoters hold 40.49% of the company, while institutional and non-institutional investors own 13.36% and 46.24%, respectively.

Meanwhile, Parag Milk Foods' premium farm-to-home dairy brand Pride of Cows has launched a refreshed brand identity designed to give the brand a younger, more contemporary and energetic image.

The company said the revamp is aimed at bringing the aspirational lifestyle associated with Pride of Cows back into focus amid an increasingly competitive dairy market. The new identity seeks to strengthen the brand's association with nourishment, wellbeing, nature and mindful living.

The transformation extends beyond the logo and includes a wider visual and sensory identity. Developed in collaboration with Pollinate, the new brand expression incorporates typography, illustrations, motion and sound created with contributions from Marta Cerda Alimbau, Daria Lada, Emanuele Colombo and Naren Chandavarkar.

The refreshed identity is intended to highlight the farm ecosystem and the brand's single-origin proposition while presenting them through a modern lifestyle-oriented approach.

Established in 1992, Parag Milk Foods is a major private dairy FMCG company with a pan-India presence.

Shares of Gujarat Themis Biosyn were trading at Rate RS 417.05 on the BSE, marking a gain of Rate RS 4.70 or 1.14% compared with its previous close of Rate RS 412.35.

The stock opened at Rate RS 413.00 and moved between an intraday high of Rate RS 420.00 and a low of Rate RS 408.80. A total of 8,884 shares changed hands on the exchange during the session.

The BSE Group 'B' stock, with a face value of Rate RS 1, has recorded a 52-week high of Rate RS 479.45 on October 27, 2025, and a 52-week low of Rate RS 225.75 on March 30, 2026.

Over the past week, the counter has traded between Rate RS 402.10 and Rate RS 438.65. The company's current market capitalisation stands at approximately Rate RS 5,452.71 crore.

As per the latest shareholding pattern, promoters own 70.86% of the company, while institutional investors hold 2.94% and non-institutional shareholders account for 26.19%.

In a key corporate development, Gujarat Themis Biosyn has secured Rate RS 585 crore through the allotment of Non-Convertible Debentures (NCDs) on a private placement basis. The Board's Committee approved the allotment at its meeting held on September 16, 2026.

The company plans to deploy the NCD proceeds for various purposes, including investment in its wholly owned subsidiary in Japan. The funds will support the proposed acquisition of MicroBiopharm Japan Co., along with meeting general corporate requirements.

Gujarat Themis Biosyn operates in the biotechnology and synthetic product manufacturing sector.

Suryoday Small Finance Bank shares are trading at RS 146.80 on the BSE, gaining RS 2.80 or 1.94% compared with the previous close of RS 144.00.

The stock started the session at RS 143.95 and moved between an intraday high of RS 147.45 and a low of RS 143.95. Around 4,839 shares have changed hands so far.

The BSE Group 'B' stock, having a face value of RS 10, has recorded a 52-week high of RS 217.50 on July 24, 2026, while its 52-week low stands at RS 115.30, touched on February 24, 2026.

Over the past week, the stock has traded between RS 142.00 and RS 150.25. The bank currently commands a market capitalisation of approximately RS 1,560.43 crore.

The company's shareholding pattern shows promoters holding 22.48%, while institutional investors and non-institutional investors hold 10.82% and 66.70%, respectively.

Meanwhile, Suryoday Small Finance Bank is looking to raise funds through the private placement of Non-Convertible Debentures (Tier II Bonds). The proposed fundraising remains subject to the necessary approvals, consents and permissions.

The Bank's Board of Directors is scheduled to meet on September 21, 2026, to consider and potentially approve the proposed issuance, among other matters.

Suryoday Small Finance Bank is a scheduled commercial bank.

NHC Foods is trading at Rate RS 2.11, registering a gain of Rate RS 0.10, or 4.98%, compared with its previous close of Rate RS 2.01 on the BSE.

The stock opened at Rate RS 2.05 and moved between a high of Rate RS 2.11 and a low of Rate RS 2.03 during the session. Around 23,122,641 shares have been traded on the counter so far.

The BSE Group 'XT' stock, having a face value of Rate RS 1, recorded a 52-week high of Rate RS 2.84 on September 4, 2026, while its 52-week low stands at Rate RS 0.59, recorded on March 30, 2026.

Over the past week, the stock has traded between Rate RS 1.83 and Rate RS 2.11. The company's current market capitalisation stands at approximately Rate RS 199.14 crore.

Institutional investors hold 13.67% of the company's equity, while non-institutional investors account for the remaining 86.33% stake.

NHC Foods Plans Controlling Stakes in Two Companies

NHC Foods has approved plans to acquire controlling interests in two food and beverage businesses — Lotmor Brands and Walya's Beverages. The proposed transactions could give NHC Foods up to an 88% stake in Lotmor Brands and up to an 80% stake in Walya's Beverages.

The acquisition consideration may be settled either in cash or through the issuance of NHC Foods equity shares at Rate RS 6.50 per share. The final consideration may also be determined after six months in line with the applicable SEBI ICDR Regulations.

According to the company, the proposed acquisitions are aimed at enhancing its procurement and distribution network while complementing its existing operations across the food and beverage value chain.

Lotmor Brands Acquisition

Lotmor Brands operates in the food and beverage sector, with activities spanning trading and manufacturing. The company was incorporated in 2018 and reported a turnover of Rate RS 2.46 crore in FY23, followed by Rate RS 2.60 crore in FY24 and Rate RS 1.80 crore in FY25.

NHC Foods said Lotmor's established operations and positive cash flows could provide complementary capabilities and support the company's plans to expand its presence in the sector.

Walya's Beverages Adds to Expansion Strategy

Walya's Beverages, incorporated in 2021, is involved in the manufacturing, trading, wholesale, import and export of food and beverage products.

The company reported no turnover in FY23, while its turnover stood at Rate RS 0.71 crore in FY24 and Rate RS 0.22 crore in FY25. The proposed acquisition is expected to expand NHC Foods' product portfolio and market coverage within the food and beverage industry.

About NHC Foods

NHC Foods is a Government Recognized Two Star Export House engaged in the export of whole and ground spices, lentils, pulses, grains, oilseeds, agricultural commodities and a range of assorted food products.

Rainbow Children’s Medicare is trading at RS 1,483.35 on the BSE, marking a gain of RS 26.55 or 1.82% compared with its previous close of RS 1,456.80.

The stock opened at RS 1,464.95 and moved between an intraday high of RS 1,505.00 and a low of RS 1,454.10. Around 2,538 shares have been traded on the exchange so far.

The BSE Group 'A' stock, with a face value of RS 10, has recorded a 52-week high of RS 1,609.00 on August 5, 2026, while its 52-week low stands at RS 1,008.75, recorded on March 2, 2026.

Over the past week, the stock has traded between RS 1,425.00 and RS 1,505.00. The company currently commands a market capitalisation of approximately RS 15,065.89 crore.

The shareholding pattern shows promoters holding 49.84% of the company. Institutional investors own 38.59%, while non-institutional shareholders account for the remaining 11.57%.

In a business development, Rainbow Children’s Medicare has started operations at its new 50-bed women’s and children’s hospital in Guntur, Andhra Pradesh. The facility is expected to broaden the company’s healthcare network in the state and improve access to specialised paediatric, women’s health, obstetrics and gynaecology services.

Rainbow Children’s Medicare operates a multi-specialty hospital network focused primarily on paediatric care and obstetrics and gynaecology services across India.

Glenmark Pharmaceuticals was trading at RS 2418.65 on the BSE, registering a marginal decline of RS 1.65, or 0.07%, compared with its previous close of RS 2417.00.

The stock opened at RS 2414.95 and moved between an intraday high of RS 2424.45 and a low of RS 2383.75. A total of 5,563 shares had changed hands on the exchange so far.

The BSE Group 'A' stock, with a face value of RS 1, has recorded a 52-week high of RS 2536.85 on August 28, 2026, while its 52-week low stands at RS 1794.00, touched on October 28, 2025.

Over the past week, the stock has traded between RS 2491.20 and RS 2383.75. Glenmark Pharmaceuticals currently has a market capitalisation of approximately RS 68,161.49 crore.

The company's shareholding pattern shows promoters holding 46.65%, while institutions own 39.53% and non-institutional investors hold 13.81%.

RYALTRIS Nasal Spray Launched in Brazil

Glenmark Pharmaceuticals, through its wholly owned subsidiary Glenmark Specialty S.A., has introduced RYALTRIS Nasal Spray in Brazil. The product is indicated for managing moderate to severe symptoms of allergic rhinitis in adults and adolescents aged 12 years and above.

The launch comes after the product received approval from Brazil's health regulator, Agencia Nacional de Vigilancia Sanitaria (ANVISA), earlier this year.

RYALTRIS represents the first olopatadine-based intranasal combination therapy launched in Brazil. The nasal spray combines olopatadine hydrochloride, an antihistamine, with mometasone furoate, a corticosteroid, providing a dual-action approach to allergic rhinitis symptom management.

Glenmark Pharmaceuticals is a research-driven global pharmaceutical company operating across Generics, Specialty and OTC segments, with a presence in more than 50 countries.

Shilpa Medicare shares were trading at Rs 964.00 on the BSE, registering a gain of Rs 23.75, or 2.53%, compared with the previous close of Rs 940.25.

The stock opened at Rs 932.40 and moved between an intraday high of Rs 974.50 and a low of Rs 910.05. A total of 82,666 shares had changed hands on the exchange so far.

The BSE Group 'A' stock, with a face value of Rs 1, has recorded a 52-week high of Rs 980.65, reached on September 7, 2026, while its 52-week low stands at Rs 260.00, recorded on January 27, 2026.

Over the past week, the stock has traded between Rs 910.05 and Rs 980.65. The company currently commands a market capitalisation of approximately Rs 18,900.05 crore.

As per the latest shareholding pattern, promoters own 40.13% of the company, while institutional investors hold 19.43% and non-institutional shareholders account for 40.43%.

Shilpa Medicare Receives Key Regulatory Approval

Shilpa Medicare has received final approval from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) for marketing authorization of OERIS (Ondansetron Extended-Release Injection, 100 mg/mL).

The company describes OERIS as the world's first extended-release injectable formulation of ondansetron, designed to provide continuous antiemetic protection for up to 120 hours, or five days, after a single administration. The product represents a first-of-its-kind approval in India as well as globally and is planned for launch in the Indian market. OERIS is also protected by an Indian patent until 2039.

The regulatory approval follows the successful completion of a multicentre, randomized, double-blind Phase III clinical trial, which evaluated the safety and effectiveness of OERIS in preventing and controlling chemotherapy-induced nausea and vomiting (CINV) among patients undergoing moderately to highly emetogenic chemotherapy.

With its extended-release technology, OERIS could reduce the need for repeated injections by enabling a single dose every five days. This is expected to improve patient convenience while also reducing the workload associated with repeated administration for healthcare professionals.

Shilpa Medicare intends to commence the commercial rollout of OERIS across India after obtaining the final marketing authorization from CDSCO.

Company Profile

Shilpa Medicare is engaged in the manufacturing and export of Active Pharmaceutical Ingredients (APIs), fine chemicals, intermediates, herbal products and speciality chemicals. The company uses advanced manufacturing technologies and follows international quality and specification standards across its product portfolio.

Shares of 3i Infotech were trading at Rs 22.58 on the BSE, registering a gain of Rs 0.58 or 2.64% compared with the previous close of Rs 22.00.

The stock opened at Rs 22.37 and moved between an intraday high of Rs 22.38 and a low of Rs 21.65. Around 1,22,952 shares had changed hands on the exchange.

The company’s BSE Group 'T' shares, carrying a face value of Rs 10, have recorded a 52-week high of Rs 27.78 on August 12, 2026, while the 52-week low stands at Rs 12.61, touched on March 16, 2026.

Over the past week, the stock has traded between Rs 21.65 and Rs 22.90. The company currently commands a market capitalisation of approximately Rs 456.29 crore.

As per the shareholding pattern, institutions hold 14.76% of the company, while non-institutional investors account for 85.24%.

Company Secures New Order

3i Infotech has received a purchase order valued at approximately Rs 1.02 crore, excluding applicable taxes, from a prominent commodity exchange in India.

Under the contract, the company will provide additional manpower and technical support for 24x7 disaster recovery operations and data centre management. The scope includes system monitoring, backup and restoration, incident handling, asset and inventory management, as well as coordination with vendors.

The contract will remain valid for three years, covering FY 2026-27 through FY 2028-29.

3i Infotech is a global information technology company focused on helping organisations drive digital transformation and improve business operations through technology-led solutions.

STL Networks shares were locked at the upper circuit of RS 36.54 on the BSE, gaining RS 1.74 or 5.00% over the previous close of RS 34.80.

The stock opened at RS 36.40 and moved between RS 35.58 and RS 36.54 during the session. Around 258,191 shares changed hands on the BSE.

The company’s BSE Group ‘B’ shares, having a face value of RS 2, touched a fresh 52-week high of RS 36.54 on September 11, 2026, compared with a 52-week low of RS 15.75 recorded on March 30, 2026. Over the past week, the stock traded between RS 29.41 and RS 36.54.

STL Networks currently has a market capitalisation of approximately RS 1,783.55 crore. The company’s shareholding pattern comprises 44.14% promoter holding, 4.36% institutional holding and 51.50% non-institutional holding.

The stock gained momentum after STL Networks received approval to incorporate a Wholly Owned Subsidiary (WOS) focused on the data centre and telecommunications infrastructure segment. The proposed subsidiary will develop, acquire, own, operate and manage data centre infrastructure, connectivity services and related solutions.

The new entity will also seek the necessary licences and regulatory approvals from the Department of Telecommunications and other authorities. Its operations are expected to cover integrated data centre and connectivity solutions, along with related activities, with an emphasis on scalability, operational flexibility and expansion in the digital infrastructure sector.

The Authorisation and Allotment Committee of STL Networks’ Board approved the proposal at its meeting held on September 11, 2026. The proposed subsidiary will be incorporated as a company limited by shares under the Companies Act, 2013.

Operating under the Invenia brand, STL Networks provides digital infrastructure and IT services to telecom operators, government and defence organisations, citizen networks and large enterprises. Its clientele spans sectors including BFSI, education, mining, energy and healthcare across India and the UK.

Atishay is witnessing strong buying interest on the BSE, with its share price currently trading at RS 153.60, registering a gain of RS 6.40 or 4.35% over the previous close of RS 147.20.

The stock opened at RS 141.25 and moved between an intraday high of RS 154.25 and a low of RS 141.00. A total of 4,956 shares have changed hands on the BSE so far.

The BSE Group 'X' stock, having a face value of RS 10 per share, recorded its 52-week high of RS 235.00 on 27 March 2026, while its 52-week low of RS 119.40 was registered on 29 September 2025.

Over the past week, the stock has traded between RS 141.00 and RS 154.75. The company currently commands a market capitalisation of approximately RS 169.33 crore.

As per the latest shareholding pattern, promoters hold a 74.65% stake in the company, while Non-Institutions account for the remaining 25.35%.

RS 4.23 Crore Work Order from Ludhiana Municipal Corporation

Atishay has received a fresh work order from the Municipal Corporation Ludhiana, Government of Punjab, for the digitisation of its official records.

The project involves digitising approximately 165 lakh pages, covering documents of different sizes as well as records such as Pay Bill Registers. The actual volume of documents may vary depending on the requirements during project execution.

The contract carries a total value of RS 4.23 crore, including applicable GST, and is scheduled to be completed over a period of three years, including the AMC phase.

The latest order strengthens Atishay's order book and provides greater visibility for future revenues. It also further establishes the company's capabilities as an implementation partner for large-scale government digitisation initiatives.

Atishay operates in the business and knowledge process services segment and focuses on technology-driven solutions. The company has developed a framework for identifying and deploying IT applications aimed at improving planning, management and socio-economic outcomes.